FierceBiotech19h
Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates
Pfizer has taken a $1.2 billion hit after reassessing the prospects of two antibody-drug conjugates (ADC) it picked up in the ...
Pfizer Shares Are Falling Today: What's Going On?
Pfizer Inc. (NYSE: PFE) shares are trading lower Tuesday after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.'s nomination for Secretary of Health and Human Services.
Pfizer’s Covid Boost Overshadowed by Kennedy Threat to Vaccines
Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., ...
Pfizer's Groundbreaking Cancer Drug Hits a Major Milestone--What It Means for Investors
BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...
Pfizer Trial For Colorectal Cancer Treatment Shows Improved Survival In Late-Stage Study
Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...
Armed robbery in Revesby19h
Pfizer's BRAFTOVI Regimen Boosts Survival in Phase 3 Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the ...
Politifact5d
No, Pfizer didn’t release a new list of COVID-19 vaccine side effects
"Pfizer just released its list of side effects of its COVID-19 vaccine," multiple Facebook posts said Jan. 26 and 27. The posts included a purported list of 46 Pfizer-BioNtech COVID-19 vaccine side ...
Pfizer's BRAFTOVI shows promise in colorectal cancer trial
NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $150 billion and annual revenue exceeding $59 billion, announced today that its Phase 3 BREAKWATER study ...
Pfizer’s Braftovi improves survival in Phase 3 colorectal cancer trial
Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...
GlobalData on MSN1d
Pfizer’s colon cancer combo approval further supported by Phase III win
Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving ...